Shots:
- Cadila has launched NuPTH an osteoporosis biosimilar of Forteo in India. The NuPTH is used for the treatment of osteoporosis and in patients with increased risk of fracture. The biosimilar NuPTH aims to be cost-effective for patients and will be available as easy to use, pre-filled disposable pen
- NuPTH is the third biosimilar launched by the company following the launch of Rituximab and Bevacizumab biosimilars, recommended in multiple indications under the brand names Ritucad and Bevaro respectively
- The launch strengthens the company’s ortho care portfolio and helps in increasing choice and access for osteoporosis care to patients in the Indian Market
Click here to read full press release/ article | Ref: Cadila Pharma | Image: Cadila Pharma
